Combined Therapy with an Angiotensin II Receptor Blocker and an Angiotensin-Converting Enzyme Inhibitor in Heart Failure

Abstract

OBJECTIVE:

To evaluate the safety, tolerability, and efficacy of chronic combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin II receptor blocker (ARB) in the management of heart failure.

DATA SOURCES:

Clinical literature was accessed through MEDLINE (January 1966–June 2000). Key search terms included angiotensin-converting enzyme inhibitor; losartan; combined modality therapy; drug effects; heart failure, congestive; and receptors, angiotensin.

DATA SYNTHESIS:

Heart failure is widely prevalent and continues to be associated with high morbidity and mortality, even with currently recommended care. At the moderate doses studied for patients with mild heart failure in brief trials, combined ACE inhibitor and ARB therapy was well tolerated and had an additive effect in reducing blood pressure and relieving symptoms of heart failure.

CONCLUSIONS:

An ARB combined with an ACE inhibitor may benefit heart failure patients who are receiving all other recommended therapies. Further trials are needed to evaluate long-term safety, effectiveness, quality of life, and survival before the combination can be recommended for routine use.

Keywords

angiotensin-converting enzyme inhibitor angiotensin receptor heart failure

Get full access to this article

View all access options for this article.

References

Packer

Cohn

, eds. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999;83:1A–38A.

Economic cost of cardiovascular diseases. American Heart Association, 2000. Available at URL: www.americanheart.org/statistics/10econom.html (accessed March 30, 2000).

Packer

Poole-Wilson

Armstrong

Cleland

Horowitz

Massie

Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312–8.

Hjalmarson

Goldstein

Fagerberg

Wedel

Waagstein

Kjekshus

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). JAMA 2000;283:1295–302.

Pitt

Zannad

Remme

Cody

Castaigne

Perez

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709–17.

Cohn

Johnson

Ziesche

Cobb

Francis

Tristani

A comparison of enalapril with hydralazine—isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325: 303–10.

Pitt

Segal

Martinez

Meurers

Cowley

Thomas

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly study, ELITE). Lancet 1997;349:747–52.

AHA: new study shows no survival advantage in heart-failure patients taking Cozaar compared to captopril. P/S/L Consulting Group Inc. November 10, 1999. Available at: URL: http://www.pslgroup.com/dg/144AE6.htm (accessed April 14, 2000).

McKelvie

Yusuf

Pericak

Avezum

Burns

Probstfield

Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999;100:1056–64.

10.

Munger

Furniss

. Angiotensin II receptor blockers: Novel therapy for heart failure? Pharmacotherapy 1996;16(2 pt 2):59S–69S.

11.

Gainer

J V

Morrow

Loveland

King

Brown

. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285–92.

12.

Rousseau

Konstam

Benedict

Donckier

Galanti

Melin

Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol 1994;73:488–93.

13.

Califf

Cohn

. Cardiac protection: Evolving role of angiotensin receptor blockers. Am Heart J 2000;139(Suppl):S15–22.

14.

Pitt

Dickstein

Benedict

Pacher

Willenheimer

Murali

The Randomized Angiotensin receptor Antagonist—ACE inhibitor Study (RAAS) — Pilot study (abstract). Circulation 1996;94(suppl I):I–428.

15.

Tocchi

Rosanio

Anzuini

Sposi

Mattioli

. Angiotensin II receptor blockade combined to ACE-inhibition improves left ventricular dilation and exercise ejection fraction in congestive heart failure (abstract). J Am Coll Cardiol 1998;31:188A.

16.

Hamroff

Katz

Mancini

Blaufarb

Bijou

Patel

Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999;99:990–2.

17.

Tonkon

Awan

Niazi

Hanley

Baruch

Wolf

A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ACE inhibitors, in heart failure. Int J Clin Pract 2000;54:11–8.

18.

Guazzi

Palermo

Pontone

Susini

Agostoni

. Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure. Am J Cardiol 1999;84:1038–43.

19.

Baruch

Anand

Cohen

Ziesche

Judd

Cohn

Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation 1999;99:2658–64.

20.

Hamroff

Blaufarb

Mancini

Katz

Bijou

Jondeau

Angiotensin-II receptor blockade further reduces afterload safely in patients maximally treated with angiotensin-converting enzyme inhibitors for heart failure. J Cardiovasc Pharmacol 1997;30:533–6.

21.

SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293–302.